1. Home
  2. /
  3. Projects
  4. /
  5. Page 3

Acceptability

Acceptability refers to meeting the policymakers, end-users, and health system requirements for a new TB vaccine for adults and adolescents. This  includes defining values from various populations, engaging communities as partners in decision-making, and having robust communication strategies in place. This follows from the WHO global framework for country introduction of new adolescent and adult TB vaccines (https://www.who.int/publications/m/item/who-global-framework-to-prepare-for-country-introduction-of-new-tb-vaccines-for-adults-and-adolescents)

New tuberculosis vaccines are in late-stage trials, but how confident is the public in high burden countries in vaccines?

With tuberculosis (TB) vaccine candidates in late-stage trials, it is important to prepare for implementation to avoid delays upon licensure. General confidence in vaccines has been identified as an anticipated barrier to introducing new TB vaccines. In the absence of detailed TB specific vaccine acceptability and confidence data, we analysed currently available vaccine confidence data in countries appearing on one of the World Health Organization (WHO) high burden lists to investigate vaccine confidence in countries with a high TB burden

An effective vaccine is only the first step: the need to create and sustain demand for TB vaccines

Understanding public willingness to receive new TB vaccines, as well as defining how to address any barriers to acceptance, will be key to ensuring that the promise of these vaccines can be fully realized. Although we can learn from previous vaccine intro ductions, it is imperative we close key research gaps specific to new TB vaccines. This will inform the development of interventions to generate and sustain high demand for TB vaccines in communities that stand to benefit the most

TB vaccine advocacy fellowship

An urgent call for increased global investment and political support for TB vaccine R&D. With the United Nations High-Level Meeting on TB taking place on 22 September 2023, this call will play an important part in amplifying the voices of the global TB community in demanding new TB vaccines. This letter is also in direct support of the recently launched call to action ‘Deadly Divide: Priorities to Close the Deadly Divide’ from the Stop TB Partnership community and non-governmental organization delegations.

Mapping the existing body of knowledge on new and repurposed TB vaccine implementation: A scoping review

By synthesizing the existing body of knowledge, this review offers comprehensive insights into the current state of research on implementation of these TB adults and adolescent vaccines. Offering insights into key dimensions: (1) epidemiological impact, (2) costing, cost-effectiveness, and/or economic impact, (3) acceptability, and the (4) feasibility of implementation; this includes implementation strategies of target populations, and health system capabilities.
Click to copy link of this header Menu